REPRORSION PHARMACEUTICALS acquires complete rights on the Rev102, potential oral therapy for the hypophosphatasis of rare bone disorders
Recuruance Pharmaceuticals Inc. (Nasdaq:Rxrx) is one of The best actions with small caps to buy according to analysts. July 8, Rallybio Corporation (Nasdaq:Rlyb) announced a final agreement to sell his interest in Rev102 to his partner in Coentreprise, Recur Pharmaceuticals. The agreement is evaluated up to $ 25 million, with an initial payment of $ 7.5 million and short -term milestones.
REV102 is an inhibitor inPP1 currently in preclinical development for the treatment of hypophosphatasis / HPP, which is a rare hereditary disorder affecting bone and dental mineralization. The program comes from a joint venture between Rallybio and Recuruion has focused on the discovery and development of new small molecule inhibitors available by ENPP1 for HPP patients.
A close -up of blank laboratory blasts and protective masks in a biotechnology research laboratory.
Rev102, the main candidate for this collaboration, entered studies to empower the early 2025. Rallybio will also receive low figures on all future net sales of Rev102 by recursion. Rallybio can also receive additional payments if RECORursion sells the Rev102 program to a third party.
RECRORATION Pharmaceuticals Inc. (NASDAQ: RXRX) is a biotechnology company at a clinical stage that decodes biology and chemistry by integrating technological innovations through biology, chemistry, automation, data science and engineering to industrialize the discovery of drugs in the United States.
Rallybio Corporation (Nasdaq: Rlyb) is a biotechnology company at a clinical stage that develops and markets life processing therapies for patients with serious and rare diseases.
Although we recognize the potential of RXRX as an investment, we believe that certain AI actions offer greater rising potential and have less risks. If you are looking for an extremely undervalued AI stock that should also benefit considerably from the Trump era tariffs and the excessive trend, see our free report on the Best short -term AI stock.
Read then: 30 actions that should double in 3 years And 11 Hidden AI stocks to buy now.
Disclosure: None. This article is initially published at Initiate monkey.
